{
    "clinical_study": {
        "@rank": "104389", 
        "arm_group": [
            {
                "arm_group_label": "bimagrumab high dose", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 52"
            }, 
            {
                "arm_group_label": "bimagrumab low dose", 
                "arm_group_type": "Experimental", 
                "description": "Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will be treated with the bimagrumab low dose administered via intravenous infusion starting Day 1 until Week 52"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Approximately 70 patients who meet all inclusion criteria and none of the exclusion criteria will receive matching placebo administered via intravenous infusion starting Day 1 until Week 52"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess if bimagrumab is safe and effective in patients with\n      muscle wasting (atrophy) after hip fracture surgery."
        }, 
        "brief_title": "Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Muscle Wasting (Atrophy) After Hip Fracture Surgery", 
        "condition_browse": {
            "mesh_term": [
                "Fractures, Bone", 
                "Hip Fractures", 
                "Muscular Atrophy", 
                "Atrophy"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have X-ray confirmed successful hip fracture repair;\n\n          -  must have completed surgical wound healing;\n\n          -  ability to walk a specified distance with or without a walking aid;\n\n          -  must weigh at least 35 kg.\n\n        Exclusion Criteria:\n\n          -  Must not have history of fracture of the same hip;\n\n          -  Must not have history of any other lower limb fractures in the past 6 months;\n\n          -  Must meet cardiovascular requirements; Must not have a chronic active infection (e.g.\n             HIV, hepatitis B or C, etc);\n\n          -  Must not have used high-dose corticosteroid medications for at least 3 months in the\n             past year;\n\n          -  Other protocol-defined inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152761", 
            "org_study_id": "CBYM338D2201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "bimagrumab high dose", 
                    "bimagrumab low dose"
                ], 
                "description": "Bimagrumab will be administered as intravenous infusion starting on Day 1 until week 52.", 
                "intervention_name": "bimagrumab", 
                "intervention_type": "Drug", 
                "other_name": "BYM338"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "Matching placebo will be administered as intravenous infusion starting on Day 1 until week 52.", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "bimagrumab", 
            "BYM338", 
            "hip fracture", 
            "elderly", 
            "controlled clinical trial", 
            "randomized", 
            "muscle wasting", 
            "atrophy"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85023"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Cajon", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92020"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80227"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tamarac", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33321"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vero Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32960"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Great Falls", 
                        "country": "United States", 
                        "state": "Montana", 
                        "zip": "59405"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altoona", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16602"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "State College", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16801"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "247-8533"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto-city", 
                        "country": "Japan", 
                        "state": "Kumamoto", 
                        "zip": "862-0976"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama-city", 
                        "country": "Japan", 
                        "state": "Okayama", 
                        "zip": "701-1192"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "4031"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Japan", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "56-week, Randomized, Multicenter, Double Blind, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Ministry of Health", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Germany: Paul-Ehrlich-Institut", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Mexico: Ministry of Health", 
                "Romania: National Medicines Agency", 
                "Spain: Spanish Agency of Medicines", 
                "Switzerland: Swissmedic", 
                "Taiwan: Center for Drug Evaluation", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline to Week 24 in total lean body mass", 
            "measure": "Change from baseline in total lean body mass measured by DXA at week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline to Week 24 and from baseline to Week 52 in gait speed (meters/sec)", 
                "measure": "Change from baseline in gait speed at week 24 and week 52", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24 and Week 52"
            }, 
            {
                "description": "Change from baseline to Week 24 and from baseline to Week 52 in physical performance as measured by the Short Physical Performance Battery", 
                "measure": "Change from baseline in short physical performance battery at week 24 and week 52", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 24 and Week 52"
            }, 
            {
                "description": "Safety and Tolerability assessed by various measures such as adverse events", 
                "measure": "Safety and Tolerability of bimagrumab assessed by various measures such as adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28, Week 32, Week 36, Week 40, Week 44, Week 48, Week 52, Week 56"
            }, 
            {
                "description": "Change from baseline to Week 52 in total lean body mass", 
                "measure": "Change from baseline in total lean body mass measured by DXA at week 52", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 52"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}